Galmed Pharmaceuticals Ltd. (GLMD) is a Biotechnology company in the Healthcare sector, currently trading at $0.71. It has a SharesGrow Score of 57/100, indicating a above average investment profile with 2 out of 7 criteria passed.
Valuation: GLMD trades at a trailing Price-to-Earnings (P/E) of -0.6 (S&P 500 average ~25) with a forward Price/Earnings-to-Growth (PEG) of 0.02.
Net income is $8M (loss), growing at +32%/yr. Net profit margin is 0% (thin). Gross margin is 0% (+0 pp trend).
Balance sheet: total debt is $0 against $16M equity (Debt-to-Equity (D/E) ratio 0, conservative). Current ratio is 7.42 (strong liquidity). Debt-to-assets is 0%. Total assets: $19M.
Analyst outlook: 10 / 16 analysts rate GLMD as buy (63%) — moderate consensus.
SharesGrow 7-Criteria breakdown: Value 100/100 (Pass), Growth 100/100 (Pass), Past 0/100 (Fail), Health 67/100 (Partial), Moat 28/100 (Fail), Future 55/100 (Partial), Income ?/100 (Fail).
